Refractory aggressive non-Hodgkin lymphoma who are ineligible forĪutologous stem cell transplant. Product candidate, axi-cel, as a treatment for patients with relapsed or Submitted a Biologics License Application to the FDA for its lead System’s ability to recognize and kill tumors. Receptor (TCR) engineered cell therapies designed to empower the immune The company is focused on chimeric antigen receptor (CAR) and T cell Long-term, durable response and eliminating the burden of chronic care. Innovative cancer immunotherapies with a goal of providing rapid, Kite is a biopharmaceutical company engaged in the development of Thereafter, Kite common stock will cease to be traded on Will be cancelled and converted into the right to receive the sameĬonsideration, without interest, received by holders who tendered in the Subsidiary of Gilead, and each share of Kite’s outstanding common stock Following the merger, Kite will become a wholly-owned Without a vote of Kite’s other stockholders pursuant to Section 251(h) Purchaser will acquire all of the remaining outstanding shares of KiteĬommon stock by means of a merger of Purchaser with and into Kite Purchaser, and shares held by any Kite stockholder who exercisedĪppraisal rights under Section 262 of the Delaware General Corporate Law Treasury), shares held by Gilead or any of its subsidiaries, including Tendered and not withdrawn and will promptly pay for such shares.Įligible Kite shares exclude shares held by Kite (or in Kite’s Gilead has accepted for payment all shares validly Guaranteed Delivery, representing approximately 3.46% of the shares Shares (including 2,003,002 shares delivered through Notices of Offer, representing approximately 66.20% of Kite’s currently outstanding That, as of one minute after 11:59 p.m., New York City time, on OctoberĢ, 2017, the initial expiration of the tender offer, approximatelyģ8,324,617 shares were validly tendered and not withdrawn in the tender Computershare TrustĬompany, N.A., the depositary for the tender offer, has advised Gilead Share, net to the seller in cash, without interest. (“Purchaser”), for all of the outstanding shares ofĬommon stock of Kite Pharma, Inc. (Nasdaq: GILD) today announced the successfulĬompletion of the tender offer by its wholly-owned subsidiary, Dodgers You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.īy using this site, you agree to the Terms of Service and Privacy Policy.Gilead Sciences, Inc. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. All timestamps are reflected in IST (Indian Standard Time).ĭISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. (for corporate data, historical price & volume, F&O data). As on 30-06-2023, the company has a total of 80.72 Crore shares outstanding.ĭATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. The company’s top management includes Dr.Y K Hamied, Ms.Samina Hamied, Mr.M K Hamied, Mr.Umang Vohra, Mr.S Radhakrishnan, Mr.Adil Zainulbhai, Mr.Ashok Sinha, Dr.Mandar Vaidya, Mr.P R Ramesh, Dr.Peter Mugyenyi, Ms.Punita Lal, Mr.Robert Stewart, Mr.Ashish Adukia, Mr.Rajendra Chopra. Company has reported net profit after tax of Rs 996.58 Crore in latest quarter. For the quarter ended 30-06-2023, the company has reported a Consolidated Total Income of Rs 6,465.18 Crore, up 10.07 % from last quarter Total Income of Rs 5,873.93 Crore and up 18.01 % from last year same quarter Total Income of Rs 5,478.62 Crore. key Products/Revenue Segments include Pharmaceuticals, Royalty Income, Other Operating Revenue, Export Incentives and Scrap for the year ending 3. Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 94,850.59 Crore) operating in Pharmaceuticals sector.
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |